Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Allysta Pharmaceutical
This is a multi-center, randomized, double-masked Phase 1/2a trial designed to evaluate the safety and tolerability of ALY688 Ophthalmic Solution in subjects with moderate to mildly severe dry eye for 8 weeks with 6 scheduled clinic visits.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Dry eye disease for \> 3 months meeting specific sign and symptom criteria
Best correct visual acuity of +0.6 logMAR or better
Willing to sign informed consent and attend study visits
Willing to comply with contraception requirements
You may not be if
Unable to meet specific sign and symptom criteria
Signs of ophthalmic allergic, inflammatory or infectious conditions
Use of contact lenses
Anatomic abnormalities preventing accurate study assessments
Use of medications that influence eye dryness
Recent ophthalmic surgery
Unwilling to suspend current treatments for dry eye disease
Clareo Health | Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
